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a b s t r a c t
The recent decline in breast cancer mortality in the USA might be due to prevention or to screening
mammography or to improved treatment protocols. We sought to determine which factors are likely to
be responsible for the observed decline in breast cancer mortality.
We used the Surveillance, Epidemiology and End Results (SEER) database to estimate incidence rates,
mortality rates, and survival from breast cancer for white women who were diagnosed with invasive
breast cancer from 1975 to 2011.
From 1975 to 2010, the mortality of breast cancer declined from 32 per 100,000 per year to 21 per
100,000 per year (34%). At the same time, the incidence increased by 30%, in particular for localized
breast cancers (62%) without a commensurate decline in the number of regional breast cancers. From
1975 to 2002, 10-year survival increased by 28% (from 64.9% to 82.8%). The increase in survival was
greater for regional cancers (23%), than for localized (10%) or for distant cancers (3%).revention and control The decline in breast cancer mortality in the USA from 1975 to 2010 is unlikely to be the result of
advances in prevention or screening. The large increase in the incidence of localized cancers without a
correspondingdecrease inadvancedbreast cancers suggests aprominent stage shift, due tooverdiagnosis.
The drop in the mortality rate could be accounted for by an improvement in cancer survival, likely due
to increased use of adjuvant chemotherapy over the period.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-NDntroduction
It is widely acknowledged that deaths from breast cancer in the
nited States have been decreasing over the past few decades but
he determinants of change are in want of explanation [1]. There
re many possible factors, but two schools of thought predom-
nate. Advocates of mammography claim that early detection is
earing fruit [2–4]. This could be through formal mammographic
creeningorbecausebetter awareness leads to smaller cancers, pal-
able or not [5]. The other school of thought attributes the decline
o adjuvant systemic therapies, including cytotoxic drugs, adju-
ant hormonal therapies and biologics such as Herceptin [6–8].
here may also be a small contribution from regional radiotherapy
9,10]. One might consider the possibility that the breast can-
ers are changing, perhaps as a consequence of evolving changing
atterns of risk factors. Moreover, the current patient population
ay not be identical to that of the past, due to the impacts of
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fertility and immigration on the ethnic distribution of American
women [11,12]. To provide compelling evidence in favor of one
or another position would require detailed information on demo-
graphics, risk factors, screening behaviors, clinical presentation,
treatments received and outcomes for a large and representative
sample of American women. Given limited information, such as
cancer incidence, stage,mortality and case-fatality at several points
in time in a ﬁxed population, one can venture an educated guess. In
the United States, this information has been compiled through the
Surveillance, Epidemiology, and End Results (SEER) registry system
and is available to researchers without cost.
In the following pages, we analyze incidence, mortality and
case-fatality rates for the last several decades and seek to measure
and explain the decline in mortality. Cancer incidence refers to the
number of new cancers diagnosed in a given calendar year, relative
to the size of thepopulation at risk and is described in termsof cases
per 100,000 women per year. Age-adjusted mortality describes the
number of women who die from breast cancer in a given calendar
year, relative to the size of the population. It is described in terms
of deaths per 100,000 women per year. The reference year is the
year of death and the deaths are from breast cancer for patients
who were treated at any time in the past (in this sense they reﬂect
prior treatment protocols). Case-fatality describes the probability
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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(1989–2009) there was no commensurate decline in cancer inci-
dence. This effectively eliminates fromconsideration thepossibility
that therewere fewer deaths fromcancer because therewere fewer
cases of cancer.
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f death from breast cancer for a patient diagnosed in a given year
nd reﬂects current treatment protocols; i.e., a woman who is diag-
osed at age 38 and dies at age 42 is included in the under 40 group
or case fatalitybut in the40–50group formortality. In theory, case-
atality considers the remaining life of the patient (who ultimately
ies of breast cancer or another cause) but for practical reasons it
s often used to describe deaths which occur in a speciﬁc follow-
p time period (e.g. ﬁve years or ten years following diagnosis). In
he event that a new, effective treatment is introduced, the impact
n case-fatality should be immediate, but there should be a lag of
everal years before an impact on mortality is noticed. In order to
implify the interpretation of these data (i.e., to remove the poten-
ial effect of demographic and ethnic change over the past 40 years)
e restrict our analyses to white women.
aterials and methods
ata source and software
The Surveillance, Epidemiology and End Results (SEER) research
atabase contains information on 2,899,726 women with invasive
reast cancer. Since its inception in 1973, SEER has been a com-
rehensive source of cancer incidence and survival in the United
tates [13]. It encompasses approximately 26%ofnewbreast cancer
iagnoses in the country. For statistical purposes, various com-
inations of the SEER registries are available, depending on the
ime period and the speciﬁc registries included. For this study, we
sed the SEER 9 registry database (Atlanta, Connecticut, Detroit,
awaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget
ound, and Utah) [14] and the SEER18 registry database (SEER13
SEER9 plus Los Angeles, San Jose-Monterey, Rural Georgia, and
he Alaska Native Tumor Registry] plus the Greater California, Ken-
ucky, Louisiana, New Jersey, and Greater Georgia [15]. We used
EER*Stat version 8.1.5 to estimate incidence and survival rates
rom SEER databases [16].
ortality
We used SEER mortality database to estimate age-adjusted
reast cancer mortality rates (deaths from breast cancer per
00,000 women) for each year from 1975 to 2010 [17]. These anal-
ses included all cases and subgroups deﬁned by age of diagnosis.
ncidence
We used the SEER9 registry database to estimate the age-
tandardized incidence rates (adjusted to the 2000 US Standard
opulation) of breast cancer in women diagnosed with breast can-
er for each year from1975 to 2011. Given that Seattle-Puget Sound
nd Atlanta registries joined the SEER program in 1974 and 1975,
espectively, we did not include the years 1973 and 1974 in our
nalyses. We included women who were classiﬁed as ‘white’ in the
EER 9 and had microscopically conﬁrmed invasive breast cancer
t diagnosis.
We used the Collaborative Staging Schema version 0204 to
elect ‘breast’ as primary site of cancer. For the cancer incidence
nalyses, we used the SEER historic stage A to deﬁne three cate-
ories of breast cancer stage at diagnosis: localized, regional and
istant breast cancer. From the SEER*Stat software, we generated
ge-standardized incidence rates (cases per 100,000 per year) for
ocalized, regional and distant breast cancers, and for all breast
ancers combined. We performed subgroup analyses to estimate
ncidence rates of localized, regional and distant breast cancer
cases per 100,000) for women <50 years and women 50 years and
bove.cer Policy 5 (2015) 8–17 9
Survival
We used SEER18 registries database to estimate breast cancer-
speciﬁc survival [15]. We selected women whose cancers were
histologically conﬁrmed, who had a known age at diagnosis and
for whom follow-up data was available. We excluded women with
missing survival time in thedatabase andwomenwith anunknown
cause of death. From 1973 we used SEER historic stage A and esti-
mated10-yearbreast cancer-speciﬁc survival for localized, regional
and distant breast cancers, and all cancers combined.
In order to estimate survival according to stage using a more
granular staging system,weusedAdjustedAmerican Joint Commit-
tee on Cancer (AJCC) 6th Stage (1988+) and classiﬁed all invasive
breast cancers into AJCC stages I–IV [18]. These data were avail-
able only for women diagnosed from 1988 on and it is premature
to estimate ten years survival, hence we estimated 5-year breast
cancer-speciﬁc survival for each stage. We performed subgroup
analyses for women <50 years and women 50 years and above,
and for women with estrogen receptor-positive and estrogen
receptor-negative tumors. We used Kaplan–Meier method of sur-
vival estimation and calculated 95% conﬁdence intervals.
Based on the 5-year breast cancer-speciﬁc survival estimates for
the two years 1990 and 2006, we calculated the absolute increase
in ﬁve-year survival over the 16-year period (percentage change
in survival from 1990 to 2006 as well as the relative improvement
in survival (%), the absolute reduction in mortality and the propor-
tionate reduction in mortality. To estimate the number of deaths
from breast cancer that were avoided in 2006, attributable to the
improvement in survival, we ﬁrst calculated the estimated num-
ber of deaths assuming 1990 ﬁve-year survival rates and compared
these to the actual number of deaths reported in the 2006 cohort.
Using the same approach we conducted subgroup analyses to esti-
mate number of deaths avoided for women <50 years (ER-positive
and ER-negative) and women 50 years and above (ER-positive and
ER-negative).
Results
From 1990 to 2010, the age-adjusted breast cancer mortality
rate from all breast cancers fell from 33.0 per 100,000 per year to
21.3 per 100,000 per year, a decline of 36% (Fig. 1). Prior to 1990,
rates were stable. The decline was 41% for women under age 40,
was 51% for women aged 40–49 and was 34% for women age 50
and older (Fig. 2).
Fig. 3 shows that during the period of rapid decline in mortality1975 1980 1985 1990 1995 2000 2005 2010
Year
Fig. 1. Breast Cancer Mortality Rates in US White: SEER 1975–2010. Abbreviations:
SEER, Surveillance, Epidemiology and End Results.
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Fig. 2. Breast Cancer Mortality Rates in US White: SEER 1975–2010, by age g
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Eig. 3. Age-standardized incidence rates of breast cancer in the US White: SEER 9,
975–2011. Abbreviations: SEER, Surveillance, Epidemiology and End Results.
If the decline in mortality were the consequence of better
creening – or more extensive screening – we would expect to
ee an increase in the incidence of early stage cancers and a com-
ensatory decline in more advanced cancers. But (after a period
f adjustment) the total incidence should remain the same. Fig. 4
hows the trends in localized cancer, in regional cancer and in dis-
ant cancer from 1975 to 2011. The incidence of localized cancer
ose by 44 per 100,000 per year over this period, beginning in 1980
nd peaking in 1999 but the incidence of advanced cancer fell by
nly 9 per 100,000 per year over the same period. The increase in
he number of early cancers is not offset by a similar drop in the
umber of more advanced cancers, contrary to the proposition that
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pidemiology and End Results.roup. Abbreviations: SEER, Surveillance, Epidemiology and End Results.
screening is the main reason for the mortality decline. The short-
fall is much greater for women over 50 (the target population for
screening) (Fig. 5) than it is for women under 50 (few of whom
had their cancer diagnosed through screening) (Fig. 6). Further-
more, mortality declined by 36% – far greater than the decline of
17% for advanced (regional and distant) cancers. The most plau-
sible explanation is that the increase in early cancers was in fact,
largely a consequence of screening, but given the small decrease
in advanced cancers (Fig. 7) the data suggest that screening leads
mainly to over-diagnosis, and not to early diagnosis.
The probability of a woman with breast cancer dying of breast
cancer in a given time period is referred to as case-fatality and
is distinguished from mortality, which refers to the probability of
woman in the population at large dying of breast cancer in a given
year. As is the case for mortality, improvements in case-fatality can
be the result of screening (i.e., advancing diagnosis) or treatment.
The complement (inverse) of case-fatality is survival and the sumof
survival and case-fatality is 100%. Data on case-fatality can be pre-
sented in termsof deaths or in termsof survival. Changes in survival
or in case-fatality can be expressed in absolute terms (deaths per
100women) or in relative terms (percentage change in the number
of deaths or survivors).
Trends in breast cancer-speciﬁc survival are presented in Fig. 8,
by stage at presentation. The greatest absolute improvement in
ten-year survival in the thirty-year period was for patients who
presentedwith regional disease (an improvement of 23%), followed
by localized disease (10%) and distant disease (3%). The rates of
improvement, assuming a linear increase with time, are presented
in Fig. 8b.
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The improvement in breast cancer survival is perhaps best
llustrated by examining ten-year case-fatality. In absolute terms,
en-year case fatality (all stages) declined by 22.2% – the same
s the absolute improvement in survival (Fig. 9). However, when
xpressed in relative terms, the decline in case-fatality is much
reater than the improvement in survival (56% and 37%, respec-
ively). Note that, as expected, the decline in mortality became
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ancer in the US White: SEER 9, 1975–2011. Abbreviations: SEER, Surveillance, Epi-
emiology and End Results.in US White: SEER 9, 1975–2011, age <50 years. Abbreviations: SEER, Surveillance,
apparent much later than the decline in case fatality (Fig. 1 above).
The lag period was about six years.
From 1975 to 2003, patients with localized disease experi-
enced a 58% decline in ten-year case-fatality (compared to a 12%
increase in survival), patients with regional disease experienced a
48% decline in ten-year case-fatality (and a 43% increase in sur-
vival) and patients with distant disease experienced a 4% decline in
ten-year case-fatality (and a 25% increase in survival) (Fig. 10).
Inorder tobetterunderstand theunderlyingbasis for thedecline
in breast cancer mortality, additional analyses were done focusing
on the SEER data from 1988 to 2008. In 1988, the AJCC staging sys-
tem was introduced, thereby increasing the number of categories
from three (localized, regional, distant) to four (stage I to stage IV).
However, given that ten-year survival data can only be determined
for patients diagnosed in 2003 and earlier, we used ﬁve-year sur-
vival (and changes in ﬁve-year survival) as the principal endpoints
of interest
In 2008, theﬁve year survival for stage I breast cancerwas 97.8%,
up from96.7% in 1988 (Table 1). A small increase of 1% appears to be
trivial, but in fact represents a 30% decline in case-fatality. Patients
with stage II cancers experienced a 6% increase in survival and a
47% decline in case fatality. For patients with stage III cancer there
was an increase of 11% in survival and a decline of 30% in case-
fatality. For women diagnosed with stage III cancer under age 50,
the increase in survival was 19% and the decline in case fatality
12 S.A. Narod et al. / Journal of Cancer Policy 5 (2015) 8–17
b 
a
 
82.40%
85.50%
90.40% 92.60%
52.30%
57.10%
68.40%
75%
13.60%
12.20% 13.60%
17%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
1975 1985 1995 2005
1
0
-y
r 
S
u
rv
iv
a
l 
(%
)
Year
Localized
Regional
Distant
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
1975 1985 1995 2005
1
0
-y
r 
S
u
rv
iv
a
l 
(%
)
Year
Localized
Regional
Distant
Fig. 8. (a) 10-year breast cancer-speciﬁc survival for localized, regional and distant breast cancer in the US White: SEER 18, 1975–2003. Abbreviations: SEER, Surveillance,
Epidemiology and End Results. (b) 10-year breast cancer-speciﬁc survival for localized, regional and distant breast cancer from 1973–2002, with linear trendline.
64.90%
70.00%
79.80%
82.80%
35.10%
30.00%
20.20%
17.20%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
1975 1985 1995 2005
P
er
ce
n
t 
(%
)
Year
Breast cancer-specific 
survival
Case fatality
Fig. 9. 10-Year breast cancer-speciﬁc survival (%) and case fatality (%) (all stages combined) in USwhite: SEER 18: 1975–2002.Abbreviations: SEER, Surveillance, Epidemiology
and End Results.
Table 1
Percent increase in 5-year survival and number of deaths avoided in stage 1–3 breast cancer in US, 1990–2006.*
AJCC
stage
Number of
cases in 2006
% of all
cases
Survival in
1990 (%)
Fatality in
1990 (%)
Survival in
2006 (%)
Fatality in
2006 (%)
Absolute increase
in survival (%)
Relative improvement
in survival (%)
Proportionate
reduction in fatality (%)
Number of
deaths avoided
I 15,578 50.4 96.1 3.9 97.8 2.2 1.7 1.7 43.6 265
II 11,136 36 86.9 13.1 92.3 7.7 5.4 5.9 41.2 601
III 4194 13.6 66.5 33.5 76.1 23.9 9.6 12.6 28.7 403
I–III 30,908 100 87.8 12.2 92.9 7.1 5.1 5.5 41.8 1269
Abbreviations: AJCC, American Joint Committee on Cancer.
* Cases restricted to women with known estrogen receptor and progesterone receptor status.
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as 50%. Among women with stage III breast cancers, the decline
n case-fatality was 37% for women with estrogen receptor positive
ancers and was 22% for women with estrogen receptor negative
ancers. There was no appreciable decline in the case-fatality for
omen with stage IV cancers (Fig. 11) and these are not considered
n the remaining analyses.
From Figs. 11–15 we can estimate how many fewer deaths have
ccurred in the SEER cohort of white women in the ﬁve year periodFig. 15. 5-Year breast cancer-speciﬁc survival for stage I–IV breast cancer in US
White: SEER 18, 1990–2006, estrogen receptor-negative tumors. Abbreviations:
SEER, Surveillance, Epidemiology and End Results.
followingadiagnosisof invasivebreast cancer (stages I–III) as a con-
sequence of the decline in case fatality from 1990 to 2006. There
were 30,908 women diagnosed in 2006; assuming a ﬁve-year case-
fatality of 12.2% (the 1990 ﬁgure) we would have expected 3771
deaths in the cohort. Assuming the ﬁve-year case fatality of 7.1%
(the 2006 ﬁgure) we would expect 2194 deaths. The difference is
1577 fewerdeaths, or 5.1 fewerdeathsper100patients.Of the1577
deaths avoided, the largest number was in stage 2 patients (601
fewer deaths) followed by stage 3 patients (403 fewer deaths) and
stage I patients (265 fewer deaths). These data are broken down
14 S.A. Narod et al. / Journal of Cancer Policy 5 (2015) 8–17
Table 2
Number of lives saved according to age and hormone receptor status; 1990–2006.*
AJCC stage Age <50 years Age ≥50 years Total cases
ER+ ER− ER+ ER−
Number of lives saved Number of lives saved Number of lives saved Number of lives saved
I 61 6 172 14 253
II 164 68 263 96 591
III 102 29 194 129 454
I–III 327 103 629 239 1298
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* Cases restricted to women with known estrogen receptor and progesterone rec
urther in Table 2 (the total number of deaths is fewer because
strogen receptor statuswas not available for all patients). Approx-
mately one-half of the deaths avoided were among women over
0 with estrogen-receptor positive cancers. About one third of the
eaths avoided were in young women (<50), who comprised 25%
f the cohort. Approximately one-quarter of the deaths avoided
ere in women with estrogen receptor negative breast cancers,
ho comprised 20% of the cohort.
iscussion
SEER data for white women diagnosed with invasive breast
ancer between 1975 and 2011 provide compelling evidence that
eaths frombreast cancerhavedeclined signiﬁcantly, despite adra-
atic increase in the number of breast cancers diagnosed over the
ame period. The period of greatest decline was 1989–2009, which
aw a fall in annual mortality from 33 per 100,000 women to 21
er 100,000 women. There was little evidence to suggest that the
ecline could be attributed to prevention or screening – there was
o decline in the incidence of all cancers and only a small decline
n advanced stage cancers – rather, the drop could be accounted for
y declining case-fatality.
A large increase in the rate of early cancers, in the absence
f a similar decline in the rate of advanced cancers, is an indi-
ator of over-diagnosis. These data have been reviewed in more
etail by Welch and Bleyer [8]. The trends in incidence do not
upport the position that screening greatly reduces breast can-
er mortality, results consistent with those of the recent Canadian
ational Breast Screening study [19,20]. In that randomized trial,
ve annual mammography screens resulted in the identiﬁcation of
12 non-palpable breast cancers, and an excess of 142 cancers in
he screening group compared to the control group, but no reduc-
ion in the number of deaths from breast cancer (180 versus 171).
otably, ﬁfteen years after the screening period stopped, the excess
f cancers in the group assigned to screening persisted, pointing to
verdiagnosis (criticisms of the study which have been numerous
nd are addressed in [21]).
Given that the number of early breast cancers nearly doubled
n the USA from 1980 to 1998 (the period when mammography
se was expanding) health promotion efforts based on advocating
creening and breast cancer awareness have been highly successful
n terms of ﬁnding more early cancers. The lack of a major decline
n more advanced cancers, however, suggests that ﬁnding cancers
hen small is not enough to impact on mortality. It is possible that
RI screening will prevent cancer deaths [22–24], but the number
f women who qualify for MRI screening at present is probably too
mall to have an impact on overall mortality rates.
These data suggest further that efforts directed toward the pre-
ention of breast cancer have not yet had an impact on mortality.
ne must consider several possibilities; e.g. that a speciﬁc inter-
ention is ineffective, that the risk factor to be avoided is rare or
hat the uptake of the prevention option is poor. However, more
undamentally, it is not necessarily the case that a program thatstatus
results in fewer breast cancers will result in fewer cancer deaths.
To date, studies on prevention have focused on cancer incidence
and not on mortality because there are many more cases of can-
cer than deaths from cancer and for statistical reasons, incidence
is easier to study. But in terms of prevention, not all cancers are
equal; for example, a drug which prevents small ER-positive can-
cers is expected to have much less impact on mortality than a
drug that prevents large ER-negative cancers. One would have to
prevent 20 localized ER-positive cancers in order to prevent a sin-
gle cancer death. Tamoxifen has been shown to prevent estrogen
receptor-positive breast cancer [25,26], but to date, no study has
shown that tamoxifen used in the preventive setting reduces breast
cancer mortality [27]. This may be due to the statistical power of
the studies, or tamoxifen may preferentially prevent those breast
cancers which carry a favorable prognosis. The ﬁve-year survival
of women with small, estrogen receptor positive, node-negative
breast cancers is excellent (stage I: 98.4%; stage II: 94.9%); but
these may recur for up to 20 years after diagnosis and the full
impact of preventing these, in terms of reducing mortality may be
delayed [28]. Aromatase inhibitors are an alternative to tamoxifen
for preventing ER-positive breast cancers, but there are currently
no chemopreventive agents which have been shown to prevent
ER-negative breast cancers.
Two factors should be considered when examining stage distri-
bution (and shift in stage distribution) over time. More intensive
surveillance of health women and more sensitive imaging tech-
niques after a diagnosis of breast cancer may cause stage shifts in
either direction. More frequent screening, more women screened
andmore sensitive screening testswill increase thenumber of early
breast cancers detected and increase the proportion of cancers that
are detected at stage I. On the other hand, after a diagnosis of breast
cancer, close scrutiny of lymph nodes for micro-metastases using
molecular and immunohistochemical techniques will increase the
number of women determined to have local spread. More and bet-
ter imaging in the context of staging will lead to the detection of
small metastases and an upward shift in stage for some patients.
Of note, the CT scan came into routine use for staging in the 1980s.
The sizes of these stage shifts are not expected to be large and are
not possible to quantitate using the current data set.
Perhaps the single most relevant risk factor to consider when
reviewing national cancer incidence trends is hormone replace-
ment therapy [29–31]. The decline in the use of postmenopausal
hormone therapy was followed rapidly by a short but steep decline
in the incidence of postmenopausal breast cancer, but a commen-
surate decline in mortality is not seen, even if a lag time is taken
into consideration (Fig. 16). The rapid decrease in the incidence of
breast cancer following cessation of HRT suggests that many of the
cancers that are ‘prevented’ are actually induced to regress; this is
a characteristic of the least aggressive types of breast cancer (e.g.
luminal A) i.e., those that are least likely to be fatal [32].
Over the last thirty years, through the study of dietary con-
sumption patterns, migration patterns and cancer incidence it was
supposed by many epidemiologists that nutrition played a key role
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n breast cancer etiology [33,34]. It followed that if a woman could
e persuaded to change her diet, she could lower her risk of breast
ancer. A ‘healthy diet’ was one that was low in fat and high in fruit
nd vegetables [35]. Several randomized trials and observational
tudies were conducted but these failed to conﬁrm the hypothesis.
otable among these studies were the lack of cancer prevention
ssociated with a low fat diet in a randomized controlled trial
f dietary intervention for breast cancer prevention among Cana-
ian women [36], the Nurses’ Health Study [34], and the lack of
mpact of fruit and vegetables on breast cancer risk in the EPIC
tudy [37]. Recently, a cohort study of circulating vitamin D levels
n the Nurses’ Health Study proved negative as well [38]. To a large
xtent, exercise and obesity, rather than diet per se have replaced
he concept of a ‘healthy’ diet in the modern breast cancer advo-
acymovement [39]. Breast cancer advocates and funding agencies
lso hope to realize the goal of cancer prevention through con-
rol of environmental hazards such as toxic workplace exposures
nd low level radiation. In 2012, the National Academy of Sciences
ublished a report entitled “Breast Cancer and the Environment, a
ife Course approach” [40]. The principal recommendations were
o avoid smoking (active and passive), to avoid alcohol, to avoid
enopausal hormonal therapy and to avoid radiation and work-
lace chemicals. Smoking is not a proven breast cancer carcinogen
41] and the contribution of alcohol is modest and is limited to
ostmenopausal ER-positive breast cancers [42–44]. HRT is dis-
ussed above. The proportions of breast cancers attributable to
adiation exposure or to workplace exposures in the United States
re unknown but are undoubtedly very small and there is no rea-
on to expect that control measures that pertain to a few percent of
he population will have an impact on overall cancer mortality. In
pite ofmountingevidence that increasing awarenessdoesnot save
ives, the EARLY actwas passed in 2010 by theUS Congresswith the
tated goals of educating and increasing breast cancer awareness
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among women younger than age 45 [45]. The legislators hope that
through increasing awareness and educating young women about
modiﬁable risk factors, they might promote (positive) behavioral
change. Unfortunately, the underlying premise thatwe can prevent
deaths from breast cancer risk by changing behavior is unproven
and the incidence of advanced breast cancer has not decreased.
The observed reductions in mortality are consistent with the
observed reductions in case-fatality. The decline in mortality from
1990 to 2001 was 27% for women under age 40, 34% for women
aged 41–50 and was 20% for women age 50 and older. The corre-
sponding decline in case fatality was 18% for women under age 40,
was 25% for women aged 41–50 and was 24% for women age 50
and older. The use of survival as an indicator of treatment efﬁcacy
is more common than case-fatality, possibly because it connotes a
positive message, but the term does not do justice to the progress
that has beenmade since 1975. For example, a one percent increase
in survival for women with localized breast cancer corresponds to
a 30% reduction in case-fatality.
In aggregate, the data in this study indicate that the decline in
mortality is attributable to a decline in case-fatality. For each stage
and for each age group, the probability of a patient dying of her
breast cancer has fallen. This decline cannot be attributable to shif-
ting of patients from a higher stage to a lower stage. The greatest
improvement in survival has been in women with regional disease.
Fig. 17 indicates that the period of greatest decline in case-
fatality was after the introduction of CMF, and tamoxifen in 1970s
[28,46,47]. The decline continued throughout the 1980s, possibly
due to theadditionof anthracyclines [48,49] and to theexpansionof
the number of patients treated with tamoxifen and chemotherapy.
The 1990s saw the introduction of adjuvant taxanes [50]. Taxanes
were introduced into adjuvant therapy in the mid-1990s and are
now in widespread use. While effective, taxanes offer a relatively
smallmarginal beneﬁt over existing chemotherapy regimens. Since
2000, the most notable changes in therapy were the introduc-
tion of adjuvant trastuzumab [51] and of the aromatase inhibitors
[52]. Trastuzamab was introduced as a treatment for patients with
metastatic disease in 1998 and then became standard as adju-
vant therapy for all women with Her2-positive cancer in 2005. The
decline in case fatality continued, but the rate of decline did not
appear to accelerate after the introduction of these drugs.
It is too early to speculate on the global impact these two adju-
vant agents on cancer mortality or case fatality. A further possible
cause of reduced case-fatality rates from the 1970s through the
1990s has been the increasing use radiation therapy. It has now
been shown that regional radiotherapy reduces the rates of distant
recurrence and death to a small extent [9,10].
The incidence of advanced stage breast cancer is relatively sta-
ble (Fig. 7). Similarly, the mean survival of patients from the time
rical timeline of breast cancer chemotherapy.
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f development of metastatic disease until death has not increased
ver this extended time period [53,54]. To some extent, this may
e an unintended consequence of the better treatments, i.e. as case
atality decreases, fewer women will develop metastatic disease,
ut those who do experience a distant recurrence may have can-
ers with an unfavorable histologic/molecular proﬁle and which
re intrinsically aggressive.
It is perhaps not unexpected that the oldest drugs should have
ad the greatest impact. In general, CMF and anthracyclines were
ntroduced in an era when the standard of care was no chemother-
py, whereas taxanes and other new therapies were introduced as
nadjunct toother chemotherapies and the incrementalbeneﬁtof a
ew drug versus a conventional drug appears smaller, compared to
he incremental beneﬁt of chemotherapy versus no chemotherapy.
urrently a CMF or an anthracycline and/or taxane-based combina-
ion is recommended for most breast cancer patients. If we assume
hat all breast cancer patients with the exception of women with
ostmenopausal women with small ER-positive cancers are eligi-
le for chemotherapy, then this comprises approximately 70% of
ll women diagnosed with breast cancer in 2009. In contrast, only
bout 15% of breast cancer patients are eligible for trastuzamab
nd the impact of trastuzamab on the total burden of mortality is
herefore expected to be much smaller.
In this study, we have estimated the number of cancer deaths
hat were avoided because of the drop in case-fatality, by age of
iagnosis, by stage and by ER-status (12 categories in total). The
umber of deaths avoided in a given category is determined by
he relative proportion of breast cancers that fall into that cate-
ory and the decline in ﬁve year case-fatality from 1990 to 2006.
n this analysis we see that the total beneﬁt is a composite of the
eneﬁts in all 12 categories combined and that each category con-
ributes to the total. The largest number of deaths avoided was in
he category of post-menopausal women with ER-positive stage II
nd stage III breast cancers; these women accounted for 27% of the
ohort but for 35% of the lives saved. This is perhaps not surprising
s these women are candidates for both tamoxifen and cytotoxic
hemotherapy.
There are several limitations to our study. Stage was introduced
n 1998 and thereforewe do not have detailed information on stage
or the entire cohort. As a consequence, our comparisons of deaths
ere based on ﬁve-year mortality and these statistics will under-
stimate the total number of deaths experienced in the cohort (and
f deaths avoided). It is not clear if the distributions of death by age,
tage and ER-status after ﬁve years are similar to the distributions
n years one to ﬁve. In particular, it is expected that the proportion
f women who are ER-positive will be higher among women who
ie in years ﬁve to ﬁfteen than in years one to ﬁve. It will be impor-
ant to readdress this cohort after ﬁve more years of follow-up so
hat most of the women who eventually die from their breast can-
er will be identiﬁed. It is possible that the ﬁve-year rates will not
eﬂect ultimate cure and it is important to readdress this cohort in
ve years. The most recent group of women studied here is that
f women who were treated in 2003. It is too early to measure
he impacts of drugs, such as trastuzamab, taxanes and the aro-
atase inhibitors on mortality in these women. Moreover, we did
ot have detailed information on the treatments received and our
peculations regarding the underlying causes of the decline inmor-
ality are based on summary statistics. Our conclusions regarding
ammography are based on the incidence of localized and dis-
ant cancers and we do not have speciﬁc information regarding
hich cancers were palpable and/or detected by mammography.
e restricted our analysis to white women for simplicity of anal-sis and it may be that the trends in African American or Asian
omen are different. The category of white women included His-
anics and non-Hispanics and we might have obscured relevant
thnic differences if they exist.
[cer Policy 5 (2015) 8–17
In conclusion, the data presented here suggest that the decline
in case-fatality that became apparent in 1980 was followed by a
prolonged decline in breast cancer mortality that began approx-
imately 10 years later. The lack of a decline in advanced cancers
in the face of an increase in localized cancers suggests that public
health initiatives aimed at prevention and early detection, while
highly successful in terms of implementing a stage shift, have not
contributed to the decline in mortality. The observed decline in
mortality is based to a large extent ondrugs introduced in the1970s
and 1980s. The protracted decline in case fatality was likely due to
incremental adjustments in the drug doses and duration (alone and
in combination) as well as a gradual expansion in the number of
women who were candidates to receive adjuvant hormonal and/or
chemotherapy.
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